logo-loader
viewAdmedus Ltd

Admedus secures milestone payment for its unique technology from 4C Medical

4C Medical’s implant utilises tissue processed by Admedus’ ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.

Admedus Ltd - Admedus secures milestone payment for its unique technology from 4C Medical
4C Medical will benefit from this technology to optimise function and durability

Admedus Ltd (ASX:AHZ) has completed the technology transfer of its unique sterilisation method as part of its ADAPT tissue treatment process to 4C Medical Technologies, Inc.

4C Medical is a Minnesota-based developer of AltaValve, a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process.

4C Medical will now pay an additional $US1 million ($US 0.44 million previously received) to use the technology to sterilise the ADAPT tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve system device.

“Transformative healing advantages” of ADAPT

The 4C Medical implant utilises tissue processed by Admedus’ clinically superior ADAPT Tissue Engineering Process for the functioning leaflet component of its valve.

4C Medical will benefit from this technology to optimise function and durability.

Admedus chief executive officer Wayne Paterson said: “For the millions of patients suffering from Mitral Regurgitation, Admedus is proud to provide the transformative healing advantages of ADAPT treated tissue with demonstrated clinically superior performance over ten years.”

Quick facts: Admedus Ltd

Price: 4.2 AUD

ASX:AHZ
Market: ASX
Market Cap: $24.82 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read